Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYD88-independent growth and survival effects of Sp1 transactivation in Waldenström macroglobulinemia

13 Mar 2014

Abstract excerpt

Sp1 transcription factor controls a pleiotropic group of genes and its aberrant activation has been reported in a number of malignancies, including multiple myeloma. In this study, we investigate and report its aberrant activation in Waldenström macroglobulinemia (WM). Both loss of and gain of Sp1 function studies have highlighted a potential oncogenic role of Sp1 in WM. We have further investigated the effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24622324
DOI: 10.1182/blood-2014-01-550509

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYD88-independent growth and survival effects of Sp1 transactivation in Waldenström macroglobulinemiaPMID 24622324Read ↗

Waldenström macroglobulinemia.Semantic proximity Read ↗

Significant Biological Role of Sp1 Transactivation in Multiple MyelomaSemantic proximity Read ↗

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Semantic proximity Read ↗

Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.Semantic proximity Read ↗

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.Semantic proximity Read ↗

MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.Semantic proximity Read ↗

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.Semantic proximity Read ↗

Expanded tumor-associated polymorphonuclear Myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activitySemantic proximity Read ↗

MYD88 L265P mutation in Waldenstrom macroglobulinemia.Semantic proximity Read ↗

Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myelomaSemantic proximity Read ↗

Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia.Semantic proximity Read ↗

Novel Approaches in Waldenström Macroglobulinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.